VACCINES FOR FELINE IMMUNODEFICIENCY VIRUS

这项提案的目标是确定 全细胞灭活疫苗和灭活全病毒 预防FIV感染的疫苗并确定其 行动机制。IWC疫苗将由灭活疫苗组成 感染FIV的同种异体淋巴样细胞。IWV疫苗将包括 灭活的无细胞丸状FIV。拟议的目标将是 通过以下具体目标实现：(1)评价效益 通过测试IWC和IWV疫苗的相对能力 在活体FIV挑战中保护猫免受FIV感染和疾病 来自同源(与疫苗相同的FIV毒株)和异源 (不同菌株)来源。疫苗的免疫原性将是 通过监测细胞和体液的发育来确定 接种疫苗的猫对几种FIV蛋白的反应。猫会是 使用低剂量和高剂量FIV进行挑战，并监测FIV的迹象 感染和临床症状；以及(2)确定感染的机制 IWC和IWV疫苗的作用。这将通过评估 以前接种的疫苗诱导的体液和细胞免疫类型 在活体病毒挑战之后。猫将在各种不同的比赛中接受挑战 免疫后间隔时间；体液和细胞免疫反应 将会受到监控。通过这种方式，免疫反应的发展可以 被监视，从而允许确定最小响应 需要保护免受FIV感染。抗体被动免疫 将在未接触疫苗的猫身上进行，然后再进行 与FIV一起挑战。这将决定幽默的意义 免疫在预防FIV感染和疾病中的作用。猫会是 用接种过的兄弟姐妹的淋巴细胞免疫(过继 转移)以确定细胞免疫在FIV保护中的作用。 我们的早期研究表明，国际捕鲸委员会 而IWV疫苗在保护猫免受FIV感染方面是有效的。 已检测到大量的FIV中和抗体 接种了IWC疫苗的猫。因此，这项研究应该有助于定义 针对FIV和其他病毒的有效疫苗的要求 慢病毒。

The objective of this proposal is to determine the ability of inactivated whole cell (IWC) vaccine and inactivated whole virus (IWV) vaccine to protect against FIV infection and to determine their mechanisms of action. The IWC vaccine will consist of inactivated FIV-infected allogeneic lymphoid cells. The IWV vaccine will consist of inactivated cell-free pelleted FIV. The proposed objective will be achieved through the following specific aims: (1) Evaluate the efficacies of the IWC and IWV vaccines by testing their relative abilities to protect cats against FIV infection and disease upon live FIV challenge from both homologous (same FIV strain as vaccine) and heterologous (different strain) sources. The immunogenicity of the vaccines will be determined by monitoring the development of cellular and humoral responses to several FIV proteins in vaccinated cats. Cats will be challenged with low and high doses of FIV and monitored for signs of FIV infection and clinical symptoms; and (2) Determine the mechanisms of action of the IWC and IWV vaccines. This will be done by evaluating the types of humoral and cellular immunities elicited by the vaccines before and after the live virus challenge. Cats will be challenged at various intervals after immunization; and humoral and cellular immune responses will be monitored. In this way, the development of immune responses can be monitored, thereby allowing determination of the minimal response required to protect against FIV. Passive immunization with antibodies from vaccinated cats will be performed on unexposed cats prior to their challenge with FIV. This will determine the significance of the humoral immunity in the prophylaxis of FIV infection and disease. Cats will be immunized with lymphoid cells from vaccinated siblings (adoptive transfer) to determine the role of cellular immunity in FIV protection. The early phase of our studies has demonstrated that both the IWC and IWV vaccines are effective in protecting cats against FIV infection. Significant levels of FIV neutralizing antibodies have been detected in IWC-vaccinated cats. Thus, this study should help define the requirements for effective vaccines against FIV and perhaps against other lentiviruses.